Skip to main content
TipRanks
Go Ultimate75% OFF

Sarepta Therapeutics (AB3A) AI Stock Analysis

0 Followers
CH:AB3A

Sarepta Therapeutics

(BX Swiss:AB3A)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Commercial franchise stabilityThe PMO franchise provides a stable commercial base while ELEVIDYS demand has shown signs of stabilization. Together, these products support a sizable recurring revenue platform and give Sarepta greater operating visibility as newer gene-therapy growth develops.
Negative Factors
Declining product revenueLower product revenue, particularly from ELEVIDYS, weakens near-term growth and makes the company more dependent on PMO franchise stability. Sustained declines could reduce resources available for pipeline investment and delay the operating leverage expected from gene-therapy expansion.

Sarepta Therapeutics Business Overview & Revenue Model

Company Description

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company...

Sarepta Therapeutics Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|Next Earnings Date:Mar 03, 2027
Earnings Call SentimentPositive

The call conveyed focused optimism, supported by stabilized ELEVIDYS demand, strong PMO performance, raised revenue guidance, positive pipeline data, upcoming DM1 and FSHD readouts, non-GAAP profitability, and nearly $1 billion of cash and investments. These positives were partially offset by year-over-year revenue declines driven by lower ELEVIDYS sales, significant take-or-pay charges and related gross-margin pressure, a third-quarter GAAP operating loss, the termination of ENVISION enrollment, and continued uncertainty around near-term ELEVIDYS growth and the non-ambulatory label.

Positive Updates

Raised 2026 Revenue Guidance
Based on strong PMO performance and stabilization in ELEVIDYS, Sarepta raised the low end of its 2026 total net product revenue guidance by $50 million and narrowed the range to $1.25 billion-$1.3 billion.

Negative Updates

Decline in Product Revenue
Third-quarter total product revenues were $324 million, a decrease of 13% year-over-year, while first-nine-month product revenues were $983 million, a decrease of 34%. The year-over-year declines were driven by lower ELEVIDYS sales.

Company Guidance

Sarepta raised the low end of its 2026 total net product revenue guidance by $50 million and narrowed the range to $1.25 billion-$1.3 billion; ELEVIDYS revenue was $83 million in the third quarter and is expected in the fourth quarter to trend in line with Q3, while the PMO franchise is expected to remain strong. Full-year combined non-GAAP R&D and SG&A expense guidance was narrowed to between $800 million and $825 million. The company expects to submit an sBLA for the under-four population mid-next year, complete enrollment of ENDEAVOR Cohort eight by the end of this year and engage with FDA in Q1 2027, share DM1 and FSHD MAD data in the coming weeks, receive higher-dose data early next year, and generate Huntington’s disease proof-of-biology data sometime around mid-year next year.

Sarepta Therapeutics Risk Analysis

Sarepta Therapeutics disclosed 66 risk factors in its most recent earnings report. Sarepta Therapeutics reported the most risks in the "Tech & Innovation" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

1 New Risk
1.Deviations from manufacturing, testing, packaging and distribution processes and procedures could result in manufacturing delays or delays in product release, which may harm our business.Q2, 2026

Sarepta Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CH:AB3A against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
TSHATSHA54Neutral$1.34B-9.53-51.87%―-13.07%-23.02%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
QUREQURE50Neutral$1.67B-6.72-96.34%―28.04%19.12%
RARERARE48Neutral$1.64B-3.10213.22%―15.76%12.63%
WVEWVE45Neutral$617.33M-2.92-44.48%―-35.07%-45.17%
SLDBSLDB42Neutral$763.42M-3.82-67.78%――28.59%

* Healthcare Sector Average

Performance Comparison

0%100%RAREQUREWVESLDBTSHADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CH:AB3A and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
RAREUltragenyx Pharmaceutical, Inc.16.08-16.46-50.58%
QUREuniQure N.V.23.81-6.52-21.50%
WVEWave Life Sciences Pte. Ltd3.13-4.02-56.22%
SLDBSolid Biosciences6.842.5057.60%
TSHATaysha Gene Therapies, Inc.4.10-0.02-0.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.